언어 선택

TRAIL

TRAIL 분자 정보

영어 이름	Tumor necrosis factor ligand superfamily member 10	시판 약물 수	0
임상 약물 수	1	표적 별명	CD253，Apo-2 ligand，TNFSF10，TNF Superfamily Member 10，APO2L，Tumor Necrosis Factor Apoptosis-Inducing Ligand Splice Variant Delta，Tumor Necrosis Factor Ligand Superfamily Member 10，Tumor Necrosis Factor (Ligand) Family， Member 10，TNF-Related Apoptosis Inducing Ligand TRAIL，TNF-Related Apoptosis-Inducing Ligand，Tumor Necrosis Factor Ligand 6A，CD253 Antigen，Protein TRAIL，TNLG6A，TL2，TRAIL，Apo-2L，Tumor Necrosis Factor (Ligand) Superfamily， Member 10，Chemokine Tumor Necrosis Factor Ligand Superfamily Member 10，Tumor Necrosis Factor Superfamily Member 10
최고 연구 개발 단계	Phase 2 Clinical

영어 이름	Tumor necrosis factor ligand superfamily member 10
표적 별명	CD253，Apo-2 ligand，TNFSF10，TNF Superfamily Member 10，APO2L，Tumor Necrosis Factor Apoptosis-Inducing Ligand Splice Variant Delta，Tumor Necrosis Factor Ligand Superfamily Member 10，Tumor Necrosis Factor (Ligand) Family， Member 10，TNF-Related Apoptosis Inducing Ligand TRAIL，TNF-Related Apoptosis-Inducing Ligand，Tumor Necrosis Factor Ligand 6A，CD253 Antigen，Protein TRAIL，TNLG6A，TL2，TRAIL，Apo-2L，Tumor Necrosis Factor (Ligand) Superfamily， Member 10，Chemokine Tumor Necrosis Factor Ligand Superfamily Member 10，Tumor Necrosis Factor Superfamily Member 10
시판 약물 수	0
임상 약물 수	1
최고 연구 개발 단계	Phase 2 Clinical

TRAIL 제품 목록

속성
Protein (2)
제품 라이브러리
온라인 (2)
종
Human (2)
태그
Fc Tag (1)His Tag (1)
마커
Unconjugated (2)

제품 번호	종	발현 시스템	제품 설명	단백질 구조	순도	특성
TRL-H5243	Human	HEK293	Human TRAIL / TNFSF10 Protein, His Tag, active trimer (MALS verified)
TRL-H5263	Human	HEK293	Human TRAIL / TNFSF10 Protein, Fc Tag, active trimer (MALS verified)

총 수량2

TRAIL분자 배경

TRAIL, also known as TNFSF10, APO2L, Apo-2L, CD253, TL2, TRAIL, TNLG6A and TNF superfamily member 10. The TRAIL gene as a drug target, induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis. TRAIL also binds the receptors DcR1 and DcR2, which do not contain a cytoplasmic domain (DcR1) or contain a truncated death domain (DcR2). DcR1 functions as a TRAIL-neutralizing decoy-receptor. The cytoplasmic domain of DcR2 is functional and activates NFkappaB. In cells expressing DcR2, TRAIL binding therefore activates NFkappaB, leading to transcription of genes known to antagonize the death signaling pathway and/or to promote inflammation.

TRAIL분자 별명

Apo-2L,TRAIL,CD253,TNFSF10,Apo-2 ligand

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
AS-1501	AS-1501	Phase 2 Clinical	Shenzhen Zhongke Amshenn Pharmaceutical Co Ltd	Acute-On-Chronic Liver Failure; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injury, Chronic; Hepatic Insufficiency; Hepatitis; Liver Failure; Myocardial Infarction; Reperfusion Injury	상세